nodes	percent_of_prediction	percent_of_DWPC	metapath
Roflumilast—PDE4D—breast cancer	0.681	1	CbGaD
Roflumilast—PDE4A—mammary gland—breast cancer	0.0031	0.148	CbGeAlD
Roflumilast—PDE4D—adipose tissue—breast cancer	0.00158	0.0752	CbGeAlD
Roflumilast—PDE4B—nipple—breast cancer	0.00153	0.0729	CbGeAlD
Roflumilast—PDE4D—adrenal gland—breast cancer	0.00142	0.0675	CbGeAlD
Roflumilast—PDE4A—adipose tissue—breast cancer	0.0014	0.0666	CbGeAlD
Roflumilast—PDE4D—female gonad—breast cancer	0.00132	0.0629	CbGeAlD
Roflumilast—PDE4A—adrenal gland—breast cancer	0.00125	0.0597	CbGeAlD
Roflumilast—PDE4A—female gonad—breast cancer	0.00117	0.0557	CbGeAlD
Roflumilast—PDE4B—endometrium—breast cancer	0.000924	0.044	CbGeAlD
Roflumilast—PDE4D—lymph node—breast cancer	0.000848	0.0404	CbGeAlD
Roflumilast—PDE4B—pituitary gland—breast cancer	0.000836	0.0398	CbGeAlD
Roflumilast—PDE4B—adipose tissue—breast cancer	0.000832	0.0397	CbGeAlD
Roflumilast—PDE4B—female reproductive system—breast cancer	0.000765	0.0365	CbGeAlD
Roflumilast—PDE4A—lymph node—breast cancer	0.000751	0.0358	CbGeAlD
Roflumilast—PDE4B—adrenal gland—breast cancer	0.000747	0.0356	CbGeAlD
Roflumilast—PDE4B—bone marrow—breast cancer	0.000722	0.0344	CbGeAlD
Roflumilast—PDE4B—female gonad—breast cancer	0.000696	0.0332	CbGeAlD
Roflumilast—PDE4B—endocrine gland—breast cancer	0.000647	0.0309	CbGeAlD
Roflumilast—PDE4B—lymph node—breast cancer	0.000448	0.0213	CbGeAlD
Roflumilast—Influenza—Doxorubicin—breast cancer	0.000117	0.000521	CcSEcCtD
Roflumilast—Palpitations—Docetaxel—breast cancer	0.000115	0.000514	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Paclitaxel—breast cancer	0.000115	0.000511	CcSEcCtD
Roflumilast—Weight decreased—Epirubicin—breast cancer	0.000114	0.00051	CcSEcCtD
Roflumilast—Malaise—Capecitabine—breast cancer	0.000114	0.000508	CcSEcCtD
Roflumilast—Hepatobiliary disease—Methotrexate—breast cancer	0.000114	0.000508	CcSEcCtD
Roflumilast—Insomnia—Paclitaxel—breast cancer	0.000114	0.000507	CcSEcCtD
Roflumilast—Vertigo—Capecitabine—breast cancer	0.000114	0.000506	CcSEcCtD
Roflumilast—Hypersensitivity—Irinotecan—breast cancer	0.000114	0.000506	CcSEcCtD
Roflumilast—Hypersensitivity—Mitoxantrone—breast cancer	0.000114	0.000506	CcSEcCtD
Roflumilast—Vomiting—Thiotepa—breast cancer	0.000113	0.000506	CcSEcCtD
Roflumilast—Pneumonia—Epirubicin—breast cancer	0.000113	0.000505	CcSEcCtD
Roflumilast—Infestation—Epirubicin—breast cancer	0.000113	0.000502	CcSEcCtD
Roflumilast—Infestation NOS—Epirubicin—breast cancer	0.000113	0.000502	CcSEcCtD
Roflumilast—Rash—Thiotepa—breast cancer	0.000113	0.000502	CcSEcCtD
Roflumilast—Dermatitis—Thiotepa—breast cancer	0.000112	0.000501	CcSEcCtD
Roflumilast—Headache—Thiotepa—breast cancer	0.000112	0.000498	CcSEcCtD
Roflumilast—Palpitations—Capecitabine—breast cancer	0.000112	0.000498	CcSEcCtD
Roflumilast—Myalgia—Docetaxel—breast cancer	0.000111	0.000495	CcSEcCtD
Roflumilast—Nausea—Vinorelbine—breast cancer	0.000111	0.000495	CcSEcCtD
Roflumilast—Dyspepsia—Paclitaxel—breast cancer	0.000111	0.000493	CcSEcCtD
Roflumilast—Asthenia—Mitoxantrone—breast cancer	0.000111	0.000493	CcSEcCtD
Roflumilast—Asthenia—Irinotecan—breast cancer	0.000111	0.000493	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.00011	0.000492	CcSEcCtD
Roflumilast—Urinary tract infection—Epirubicin—breast cancer	0.00011	0.000488	CcSEcCtD
Roflumilast—Decreased appetite—Paclitaxel—breast cancer	0.000109	0.000487	CcSEcCtD
Roflumilast—Hypersensitivity—Fluorouracil—breast cancer	0.000109	0.000485	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000109	0.000484	CcSEcCtD
Roflumilast—Fatigue—Paclitaxel—breast cancer	0.000108	0.000483	CcSEcCtD
Roflumilast—Asthenia—Gemcitabine—breast cancer	0.000108	0.00048	CcSEcCtD
Roflumilast—Myalgia—Capecitabine—breast cancer	0.000108	0.00048	CcSEcCtD
Roflumilast—Constipation—Paclitaxel—breast cancer	0.000107	0.000479	CcSEcCtD
Roflumilast—Anxiety—Capecitabine—breast cancer	0.000107	0.000478	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000107	0.000476	CcSEcCtD
Roflumilast—Hepatobiliary disease—Epirubicin—breast cancer	0.000107	0.000475	CcSEcCtD
Roflumilast—Discomfort—Capecitabine—breast cancer	0.000106	0.000474	CcSEcCtD
Roflumilast—Nausea—Thiotepa—breast cancer	0.000106	0.000473	CcSEcCtD
Roflumilast—Infection—Docetaxel—breast cancer	0.000106	0.000472	CcSEcCtD
Roflumilast—Weight decreased—Doxorubicin—breast cancer	0.000106	0.000472	CcSEcCtD
Roflumilast—Sinusitis—Epirubicin—breast cancer	0.000106	0.000471	CcSEcCtD
Roflumilast—Diarrhoea—Irinotecan—breast cancer	0.000105	0.00047	CcSEcCtD
Roflumilast—Diarrhoea—Mitoxantrone—breast cancer	0.000105	0.00047	CcSEcCtD
Roflumilast—Pneumonia—Doxorubicin—breast cancer	0.000105	0.000467	CcSEcCtD
Roflumilast—Nervous system disorder—Docetaxel—breast cancer	0.000104	0.000466	CcSEcCtD
Roflumilast—Infestation NOS—Doxorubicin—breast cancer	0.000104	0.000465	CcSEcCtD
Roflumilast—Infestation—Doxorubicin—breast cancer	0.000104	0.000465	CcSEcCtD
Roflumilast—Feeling abnormal—Paclitaxel—breast cancer	0.000104	0.000462	CcSEcCtD
Roflumilast—Skin disorder—Docetaxel—breast cancer	0.000103	0.000461	CcSEcCtD
Roflumilast—Gastrointestinal pain—Paclitaxel—breast cancer	0.000103	0.000458	CcSEcCtD
Roflumilast—Diarrhoea—Gemcitabine—breast cancer	0.000103	0.000458	CcSEcCtD
Roflumilast—Infection—Capecitabine—breast cancer	0.000102	0.000457	CcSEcCtD
Roflumilast—Dizziness—Irinotecan—breast cancer	0.000102	0.000454	CcSEcCtD
Roflumilast—Rhinitis—Epirubicin—breast cancer	0.000101	0.000452	CcSEcCtD
Roflumilast—Urinary tract infection—Doxorubicin—breast cancer	0.000101	0.000452	CcSEcCtD
Roflumilast—Nervous system disorder—Capecitabine—breast cancer	0.000101	0.000451	CcSEcCtD
Roflumilast—Diarrhoea—Fluorouracil—breast cancer	0.000101	0.00045	CcSEcCtD
Roflumilast—Cardiac disorder—Methotrexate—breast cancer	0.0001	0.000447	CcSEcCtD
Roflumilast—Skin disorder—Capecitabine—breast cancer	0.0001	0.000447	CcSEcCtD
Roflumilast—Urticaria—Paclitaxel—breast cancer	9.99e-05	0.000445	CcSEcCtD
Roflumilast—Connective tissue disorder—Epirubicin—breast cancer	9.94e-05	0.000443	CcSEcCtD
Roflumilast—Abdominal pain—Paclitaxel—breast cancer	9.94e-05	0.000443	CcSEcCtD
Roflumilast—Hepatobiliary disease—Doxorubicin—breast cancer	9.86e-05	0.00044	CcSEcCtD
Roflumilast—Vomiting—Mitoxantrone—breast cancer	9.8e-05	0.000437	CcSEcCtD
Roflumilast—Vomiting—Irinotecan—breast cancer	9.8e-05	0.000437	CcSEcCtD
Roflumilast—Sinusitis—Doxorubicin—breast cancer	9.78e-05	0.000436	CcSEcCtD
Roflumilast—Immune system disorder—Methotrexate—breast cancer	9.76e-05	0.000435	CcSEcCtD
Roflumilast—Dizziness—Fluorouracil—breast cancer	9.76e-05	0.000435	CcSEcCtD
Roflumilast—Mediastinal disorder—Methotrexate—breast cancer	9.74e-05	0.000434	CcSEcCtD
Roflumilast—Rash—Irinotecan—breast cancer	9.72e-05	0.000433	CcSEcCtD
Roflumilast—Rash—Mitoxantrone—breast cancer	9.72e-05	0.000433	CcSEcCtD
Roflumilast—Dermatitis—Irinotecan—breast cancer	9.71e-05	0.000433	CcSEcCtD
Roflumilast—Dermatitis—Mitoxantrone—breast cancer	9.71e-05	0.000433	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Docetaxel—breast cancer	9.71e-05	0.000433	CcSEcCtD
Roflumilast—Headache—Mitoxantrone—breast cancer	9.66e-05	0.00043	CcSEcCtD
Roflumilast—Headache—Irinotecan—breast cancer	9.66e-05	0.00043	CcSEcCtD
Roflumilast—Insomnia—Docetaxel—breast cancer	9.64e-05	0.00043	CcSEcCtD
Roflumilast—Vomiting—Gemcitabine—breast cancer	9.55e-05	0.000426	CcSEcCtD
Roflumilast—Mental disorder—Methotrexate—breast cancer	9.47e-05	0.000422	CcSEcCtD
Roflumilast—Rash—Gemcitabine—breast cancer	9.47e-05	0.000422	CcSEcCtD
Roflumilast—Dermatitis—Gemcitabine—breast cancer	9.46e-05	0.000422	CcSEcCtD
Roflumilast—Malnutrition—Methotrexate—breast cancer	9.41e-05	0.000419	CcSEcCtD
Roflumilast—Headache—Gemcitabine—breast cancer	9.41e-05	0.000419	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Capecitabine—breast cancer	9.4e-05	0.000419	CcSEcCtD
Roflumilast—Cardiac disorder—Epirubicin—breast cancer	9.39e-05	0.000418	CcSEcCtD
Roflumilast—Vomiting—Fluorouracil—breast cancer	9.39e-05	0.000418	CcSEcCtD
Roflumilast—Rhinitis—Doxorubicin—breast cancer	9.38e-05	0.000418	CcSEcCtD
Roflumilast—Dyspepsia—Docetaxel—breast cancer	9.38e-05	0.000418	CcSEcCtD
Roflumilast—Insomnia—Capecitabine—breast cancer	9.33e-05	0.000416	CcSEcCtD
Roflumilast—Rash—Fluorouracil—breast cancer	9.31e-05	0.000415	CcSEcCtD
Roflumilast—Dermatitis—Fluorouracil—breast cancer	9.3e-05	0.000415	CcSEcCtD
Roflumilast—Decreased appetite—Docetaxel—breast cancer	9.26e-05	0.000413	CcSEcCtD
Roflumilast—Hypersensitivity—Paclitaxel—breast cancer	9.26e-05	0.000413	CcSEcCtD
Roflumilast—Headache—Fluorouracil—breast cancer	9.25e-05	0.000412	CcSEcCtD
Roflumilast—Dysgeusia—Methotrexate—breast cancer	9.21e-05	0.000411	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Docetaxel—breast cancer	9.2e-05	0.00041	CcSEcCtD
Roflumilast—Connective tissue disorder—Doxorubicin—breast cancer	9.2e-05	0.00041	CcSEcCtD
Roflumilast—Fatigue—Docetaxel—breast cancer	9.19e-05	0.000409	CcSEcCtD
Roflumilast—Nausea—Mitoxantrone—breast cancer	9.15e-05	0.000408	CcSEcCtD
Roflumilast—Nausea—Irinotecan—breast cancer	9.15e-05	0.000408	CcSEcCtD
Roflumilast—Immune system disorder—Epirubicin—breast cancer	9.14e-05	0.000407	CcSEcCtD
Roflumilast—Mediastinal disorder—Epirubicin—breast cancer	9.12e-05	0.000406	CcSEcCtD
Roflumilast—Constipation—Docetaxel—breast cancer	9.11e-05	0.000406	CcSEcCtD
Roflumilast—Back pain—Methotrexate—breast cancer	9.1e-05	0.000406	CcSEcCtD
Roflumilast—Dyspepsia—Capecitabine—breast cancer	9.08e-05	0.000405	CcSEcCtD
Roflumilast—Asthenia—Paclitaxel—breast cancer	9.02e-05	0.000402	CcSEcCtD
Roflumilast—Decreased appetite—Capecitabine—breast cancer	8.97e-05	0.0004	CcSEcCtD
Roflumilast—Nausea—Gemcitabine—breast cancer	8.92e-05	0.000398	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Capecitabine—breast cancer	8.91e-05	0.000397	CcSEcCtD
Roflumilast—Fatigue—Capecitabine—breast cancer	8.89e-05	0.000396	CcSEcCtD
Roflumilast—Mental disorder—Epirubicin—breast cancer	8.86e-05	0.000395	CcSEcCtD
Roflumilast—Constipation—Capecitabine—breast cancer	8.82e-05	0.000393	CcSEcCtD
Roflumilast—Malnutrition—Epirubicin—breast cancer	8.81e-05	0.000393	CcSEcCtD
Roflumilast—Feeling abnormal—Docetaxel—breast cancer	8.78e-05	0.000391	CcSEcCtD
Roflumilast—Nausea—Fluorouracil—breast cancer	8.77e-05	0.000391	CcSEcCtD
Roflumilast—Ill-defined disorder—Methotrexate—breast cancer	8.73e-05	0.000389	CcSEcCtD
Roflumilast—Gastrointestinal pain—Docetaxel—breast cancer	8.71e-05	0.000388	CcSEcCtD
Roflumilast—Cardiac disorder—Doxorubicin—breast cancer	8.69e-05	0.000387	CcSEcCtD
Roflumilast—Tension—Epirubicin—breast cancer	8.64e-05	0.000385	CcSEcCtD
Roflumilast—Dysgeusia—Epirubicin—breast cancer	8.62e-05	0.000384	CcSEcCtD
Roflumilast—Diarrhoea—Paclitaxel—breast cancer	8.6e-05	0.000383	CcSEcCtD
Roflumilast—Nervousness—Epirubicin—breast cancer	8.55e-05	0.000381	CcSEcCtD
Roflumilast—Back pain—Epirubicin—breast cancer	8.52e-05	0.00038	CcSEcCtD
Roflumilast—Feeling abnormal—Capecitabine—breast cancer	8.5e-05	0.000379	CcSEcCtD
Roflumilast—Malaise—Methotrexate—breast cancer	8.48e-05	0.000378	CcSEcCtD
Roflumilast—Muscle spasms—Epirubicin—breast cancer	8.47e-05	0.000377	CcSEcCtD
Roflumilast—Immune system disorder—Doxorubicin—breast cancer	8.45e-05	0.000377	CcSEcCtD
Roflumilast—Vertigo—Methotrexate—breast cancer	8.45e-05	0.000377	CcSEcCtD
Roflumilast—Gastrointestinal pain—Capecitabine—breast cancer	8.44e-05	0.000376	CcSEcCtD
Roflumilast—Mediastinal disorder—Doxorubicin—breast cancer	8.43e-05	0.000376	CcSEcCtD
Roflumilast—Abdominal pain—Docetaxel—breast cancer	8.42e-05	0.000375	CcSEcCtD
Roflumilast—Dizziness—Paclitaxel—breast cancer	8.31e-05	0.000371	CcSEcCtD
Roflumilast—Mental disorder—Doxorubicin—breast cancer	8.2e-05	0.000366	CcSEcCtD
Roflumilast—Urticaria—Capecitabine—breast cancer	8.19e-05	0.000365	CcSEcCtD
Roflumilast—Ill-defined disorder—Epirubicin—breast cancer	8.17e-05	0.000364	CcSEcCtD
Roflumilast—Abdominal pain—Capecitabine—breast cancer	8.15e-05	0.000364	CcSEcCtD
Roflumilast—Malnutrition—Doxorubicin—breast cancer	8.15e-05	0.000363	CcSEcCtD
Roflumilast—Myalgia—Methotrexate—breast cancer	8.01e-05	0.000357	CcSEcCtD
Roflumilast—Tension—Doxorubicin—breast cancer	7.99e-05	0.000356	CcSEcCtD
Roflumilast—Vomiting—Paclitaxel—breast cancer	7.99e-05	0.000356	CcSEcCtD
Roflumilast—Dysgeusia—Doxorubicin—breast cancer	7.98e-05	0.000356	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	7.96e-05	0.000355	CcSEcCtD
Roflumilast—Malaise—Epirubicin—breast cancer	7.94e-05	0.000354	CcSEcCtD
Roflumilast—Rash—Paclitaxel—breast cancer	7.93e-05	0.000353	CcSEcCtD
Roflumilast—Dermatitis—Paclitaxel—breast cancer	7.92e-05	0.000353	CcSEcCtD
Roflumilast—Discomfort—Methotrexate—breast cancer	7.91e-05	0.000353	CcSEcCtD
Roflumilast—Nervousness—Doxorubicin—breast cancer	7.91e-05	0.000353	CcSEcCtD
Roflumilast—Vertigo—Epirubicin—breast cancer	7.91e-05	0.000353	CcSEcCtD
Roflumilast—Back pain—Doxorubicin—breast cancer	7.88e-05	0.000351	CcSEcCtD
Roflumilast—Headache—Paclitaxel—breast cancer	7.87e-05	0.000351	CcSEcCtD
Roflumilast—Hypersensitivity—Docetaxel—breast cancer	7.85e-05	0.00035	CcSEcCtD
Roflumilast—Muscle spasms—Doxorubicin—breast cancer	7.83e-05	0.000349	CcSEcCtD
Roflumilast—Palpitations—Epirubicin—breast cancer	7.78e-05	0.000347	CcSEcCtD
Roflumilast—Asthenia—Docetaxel—breast cancer	7.64e-05	0.000341	CcSEcCtD
Roflumilast—Infection—Methotrexate—breast cancer	7.63e-05	0.00034	CcSEcCtD
Roflumilast—Hypersensitivity—Capecitabine—breast cancer	7.6e-05	0.000339	CcSEcCtD
Roflumilast—Ill-defined disorder—Doxorubicin—breast cancer	7.56e-05	0.000337	CcSEcCtD
Roflumilast—Nervous system disorder—Methotrexate—breast cancer	7.53e-05	0.000336	CcSEcCtD
Roflumilast—Myalgia—Epirubicin—breast cancer	7.5e-05	0.000334	CcSEcCtD
Roflumilast—Anxiety—Epirubicin—breast cancer	7.47e-05	0.000333	CcSEcCtD
Roflumilast—Nausea—Paclitaxel—breast cancer	7.47e-05	0.000333	CcSEcCtD
Roflumilast—Skin disorder—Methotrexate—breast cancer	7.46e-05	0.000333	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	7.44e-05	0.000332	CcSEcCtD
Roflumilast—Discomfort—Epirubicin—breast cancer	7.41e-05	0.00033	CcSEcCtD
Roflumilast—Asthenia—Capecitabine—breast cancer	7.4e-05	0.00033	CcSEcCtD
Roflumilast—Malaise—Doxorubicin—breast cancer	7.35e-05	0.000328	CcSEcCtD
Roflumilast—Vertigo—Doxorubicin—breast cancer	7.32e-05	0.000326	CcSEcCtD
Roflumilast—Diarrhoea—Docetaxel—breast cancer	7.29e-05	0.000325	CcSEcCtD
Roflumilast—Palpitations—Doxorubicin—breast cancer	7.2e-05	0.000321	CcSEcCtD
Roflumilast—Infection—Epirubicin—breast cancer	7.14e-05	0.000318	CcSEcCtD
Roflumilast—Diarrhoea—Capecitabine—breast cancer	7.06e-05	0.000315	CcSEcCtD
Roflumilast—Nervous system disorder—Epirubicin—breast cancer	7.05e-05	0.000314	CcSEcCtD
Roflumilast—Dizziness—Docetaxel—breast cancer	7.05e-05	0.000314	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Methotrexate—breast cancer	7e-05	0.000312	CcSEcCtD
Roflumilast—Skin disorder—Epirubicin—breast cancer	6.98e-05	0.000311	CcSEcCtD
Roflumilast—Insomnia—Methotrexate—breast cancer	6.95e-05	0.00031	CcSEcCtD
Roflumilast—Myalgia—Doxorubicin—breast cancer	6.94e-05	0.000309	CcSEcCtD
Roflumilast—Anxiety—Doxorubicin—breast cancer	6.91e-05	0.000308	CcSEcCtD
Roflumilast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	6.89e-05	0.000307	CcSEcCtD
Roflumilast—Discomfort—Doxorubicin—breast cancer	6.85e-05	0.000306	CcSEcCtD
Roflumilast—Dizziness—Capecitabine—breast cancer	6.82e-05	0.000304	CcSEcCtD
Roflumilast—Vomiting—Docetaxel—breast cancer	6.77e-05	0.000302	CcSEcCtD
Roflumilast—Dyspepsia—Methotrexate—breast cancer	6.76e-05	0.000301	CcSEcCtD
Roflumilast—Rash—Docetaxel—breast cancer	6.72e-05	0.000299	CcSEcCtD
Roflumilast—Dermatitis—Docetaxel—breast cancer	6.71e-05	0.000299	CcSEcCtD
Roflumilast—Decreased appetite—Methotrexate—breast cancer	6.68e-05	0.000298	CcSEcCtD
Roflumilast—Headache—Docetaxel—breast cancer	6.67e-05	0.000298	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Methotrexate—breast cancer	6.63e-05	0.000296	CcSEcCtD
Roflumilast—Fatigue—Methotrexate—breast cancer	6.62e-05	0.000295	CcSEcCtD
Roflumilast—Infection—Doxorubicin—breast cancer	6.61e-05	0.000294	CcSEcCtD
Roflumilast—Vomiting—Capecitabine—breast cancer	6.56e-05	0.000292	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Epirubicin—breast cancer	6.55e-05	0.000292	CcSEcCtD
Roflumilast—Nervous system disorder—Doxorubicin—breast cancer	6.52e-05	0.000291	CcSEcCtD
Roflumilast—Rash—Capecitabine—breast cancer	6.5e-05	0.00029	CcSEcCtD
Roflumilast—Insomnia—Epirubicin—breast cancer	6.5e-05	0.00029	CcSEcCtD
Roflumilast—Dermatitis—Capecitabine—breast cancer	6.5e-05	0.00029	CcSEcCtD
Roflumilast—Headache—Capecitabine—breast cancer	6.46e-05	0.000288	CcSEcCtD
Roflumilast—Skin disorder—Doxorubicin—breast cancer	6.46e-05	0.000288	CcSEcCtD
Roflumilast—Nausea—Docetaxel—breast cancer	6.33e-05	0.000282	CcSEcCtD
Roflumilast—Feeling abnormal—Methotrexate—breast cancer	6.33e-05	0.000282	CcSEcCtD
Roflumilast—Dyspepsia—Epirubicin—breast cancer	6.33e-05	0.000282	CcSEcCtD
Roflumilast—Gastrointestinal pain—Methotrexate—breast cancer	6.28e-05	0.00028	CcSEcCtD
Roflumilast—Decreased appetite—Epirubicin—breast cancer	6.25e-05	0.000278	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Epirubicin—breast cancer	6.2e-05	0.000277	CcSEcCtD
Roflumilast—Fatigue—Epirubicin—breast cancer	6.2e-05	0.000276	CcSEcCtD
Roflumilast—Constipation—Epirubicin—breast cancer	6.15e-05	0.000274	CcSEcCtD
Roflumilast—Nausea—Capecitabine—breast cancer	6.13e-05	0.000273	CcSEcCtD
Roflumilast—Urticaria—Methotrexate—breast cancer	6.1e-05	0.000272	CcSEcCtD
Roflumilast—Abdominal pain—Methotrexate—breast cancer	6.07e-05	0.000271	CcSEcCtD
Roflumilast—Musculoskeletal discomfort—Doxorubicin—breast cancer	6.06e-05	0.00027	CcSEcCtD
Roflumilast—Insomnia—Doxorubicin—breast cancer	6.01e-05	0.000268	CcSEcCtD
Roflumilast—Feeling abnormal—Epirubicin—breast cancer	5.92e-05	0.000264	CcSEcCtD
Roflumilast—Gastrointestinal pain—Epirubicin—breast cancer	5.88e-05	0.000262	CcSEcCtD
Roflumilast—Dyspepsia—Doxorubicin—breast cancer	5.85e-05	0.000261	CcSEcCtD
Roflumilast—Decreased appetite—Doxorubicin—breast cancer	5.78e-05	0.000258	CcSEcCtD
Roflumilast—Gastrointestinal disorder—Doxorubicin—breast cancer	5.74e-05	0.000256	CcSEcCtD
Roflumilast—Fatigue—Doxorubicin—breast cancer	5.73e-05	0.000256	CcSEcCtD
Roflumilast—Urticaria—Epirubicin—breast cancer	5.71e-05	0.000255	CcSEcCtD
Roflumilast—Constipation—Doxorubicin—breast cancer	5.69e-05	0.000253	CcSEcCtD
Roflumilast—Abdominal pain—Epirubicin—breast cancer	5.68e-05	0.000253	CcSEcCtD
Roflumilast—Hypersensitivity—Methotrexate—breast cancer	5.66e-05	0.000252	CcSEcCtD
Roflumilast—Asthenia—Methotrexate—breast cancer	5.51e-05	0.000246	CcSEcCtD
Roflumilast—Feeling abnormal—Doxorubicin—breast cancer	5.48e-05	0.000244	CcSEcCtD
Roflumilast—Gastrointestinal pain—Doxorubicin—breast cancer	5.44e-05	0.000242	CcSEcCtD
Roflumilast—Hypersensitivity—Epirubicin—breast cancer	5.29e-05	0.000236	CcSEcCtD
Roflumilast—Urticaria—Doxorubicin—breast cancer	5.28e-05	0.000235	CcSEcCtD
Roflumilast—Abdominal pain—Doxorubicin—breast cancer	5.26e-05	0.000234	CcSEcCtD
Roflumilast—Diarrhoea—Methotrexate—breast cancer	5.25e-05	0.000234	CcSEcCtD
Roflumilast—Asthenia—Epirubicin—breast cancer	5.16e-05	0.00023	CcSEcCtD
Roflumilast—Dizziness—Methotrexate—breast cancer	5.08e-05	0.000226	CcSEcCtD
Roflumilast—Diarrhoea—Epirubicin—breast cancer	4.92e-05	0.000219	CcSEcCtD
Roflumilast—Hypersensitivity—Doxorubicin—breast cancer	4.9e-05	0.000218	CcSEcCtD
Roflumilast—Vomiting—Methotrexate—breast cancer	4.88e-05	0.000218	CcSEcCtD
Roflumilast—Rash—Methotrexate—breast cancer	4.84e-05	0.000216	CcSEcCtD
Roflumilast—Dermatitis—Methotrexate—breast cancer	4.84e-05	0.000216	CcSEcCtD
Roflumilast—Headache—Methotrexate—breast cancer	4.81e-05	0.000214	CcSEcCtD
Roflumilast—Asthenia—Doxorubicin—breast cancer	4.77e-05	0.000213	CcSEcCtD
Roflumilast—Dizziness—Epirubicin—breast cancer	4.75e-05	0.000212	CcSEcCtD
Roflumilast—Vomiting—Epirubicin—breast cancer	4.57e-05	0.000204	CcSEcCtD
Roflumilast—Nausea—Methotrexate—breast cancer	4.56e-05	0.000203	CcSEcCtD
Roflumilast—Diarrhoea—Doxorubicin—breast cancer	4.55e-05	0.000203	CcSEcCtD
Roflumilast—Rash—Epirubicin—breast cancer	4.53e-05	0.000202	CcSEcCtD
Roflumilast—Dermatitis—Epirubicin—breast cancer	4.53e-05	0.000202	CcSEcCtD
Roflumilast—Headache—Epirubicin—breast cancer	4.5e-05	0.000201	CcSEcCtD
Roflumilast—Dizziness—Doxorubicin—breast cancer	4.4e-05	0.000196	CcSEcCtD
Roflumilast—Nausea—Epirubicin—breast cancer	4.27e-05	0.00019	CcSEcCtD
Roflumilast—Vomiting—Doxorubicin—breast cancer	4.23e-05	0.000188	CcSEcCtD
Roflumilast—Rash—Doxorubicin—breast cancer	4.19e-05	0.000187	CcSEcCtD
Roflumilast—Dermatitis—Doxorubicin—breast cancer	4.19e-05	0.000187	CcSEcCtD
Roflumilast—Headache—Doxorubicin—breast cancer	4.17e-05	0.000186	CcSEcCtD
Roflumilast—Nausea—Doxorubicin—breast cancer	3.95e-05	0.000176	CcSEcCtD
Roflumilast—PDE4B—Signaling Pathways—HES1—breast cancer	2.05e-05	0.000277	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SPP1—breast cancer	2.05e-05	0.000277	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL2—breast cancer	2.05e-05	0.000277	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TERT—breast cancer	2.04e-05	0.000276	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—CXCL8—breast cancer	2.04e-05	0.000275	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PLA2G4A—breast cancer	2.04e-05	0.000275	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NCOR1—breast cancer	2.04e-05	0.000275	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NFKBIA—breast cancer	2.04e-05	0.000275	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ERBB3—breast cancer	2.03e-05	0.000274	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FGFR2—breast cancer	2.03e-05	0.000273	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOTCH1—breast cancer	2.02e-05	0.000273	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGF1—breast cancer	2.02e-05	0.000272	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CSF2—breast cancer	2.02e-05	0.000272	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—RAF1—breast cancer	2.01e-05	0.000272	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NRG1—breast cancer	2e-05	0.00027	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—H2AFX—breast cancer	1.99e-05	0.000268	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—IL2—breast cancer	1.99e-05	0.000268	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FGFR1—breast cancer	1.98e-05	0.000268	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—APC—breast cancer	1.98e-05	0.000267	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CG—breast cancer	1.98e-05	0.000267	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KIT—breast cancer	1.98e-05	0.000267	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—E2F1—breast cancer	1.98e-05	0.000266	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CB—breast cancer	1.97e-05	0.000265	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EGF—breast cancer	1.95e-05	0.000264	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HIF1A—breast cancer	1.95e-05	0.000263	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL2—breast cancer	1.95e-05	0.000263	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TERT—breast cancer	1.94e-05	0.000262	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—LEP—breast cancer	1.91e-05	0.000257	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SPP1—breast cancer	1.9e-05	0.000256	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—MAPK3—breast cancer	1.89e-05	0.000255	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CAV1—breast cancer	1.89e-05	0.000255	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—CXCL8—breast cancer	1.89e-05	0.000255	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FGFR1—breast cancer	1.89e-05	0.000255	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ERBB3—breast cancer	1.88e-05	0.000253	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGFR2—breast cancer	1.87e-05	0.000253	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KDR—breast cancer	1.87e-05	0.000252	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HIF1A—breast cancer	1.86e-05	0.000251	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—BRAF—breast cancer	1.86e-05	0.000251	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ESR1—breast cancer	1.82e-05	0.000246	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—LEP—breast cancer	1.82e-05	0.000245	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IGF1—breast cancer	1.81e-05	0.000244	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AKT2—breast cancer	1.81e-05	0.000244	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL2—breast cancer	1.81e-05	0.000244	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—EGFR—breast cancer	1.8e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TERT—breast cancer	1.8e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CAV1—breast cancer	1.8e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—FN1—breast cancer	1.8e-05	0.000243	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KDR—breast cancer	1.78e-05	0.00024	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NFKBIA—breast cancer	1.78e-05	0.00024	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOTCH1—breast cancer	1.76e-05	0.000237	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FGFR1—breast cancer	1.75e-05	0.000236	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CD—breast cancer	1.74e-05	0.000234	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ESR1—breast cancer	1.73e-05	0.000234	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—PIK3CA—breast cancer	1.72e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—APC—breast cancer	1.72e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CG—breast cancer	1.72e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KIT—breast cancer	1.72e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HIF1A—breast cancer	1.72e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SERPINE1—breast cancer	1.72e-05	0.000232	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—FN1—breast cancer	1.71e-05	0.000231	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—KRAS—breast cancer	1.7e-05	0.000229	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EGF—breast cancer	1.7e-05	0.000229	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NFKBIA—breast cancer	1.69e-05	0.000228	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—LEP—breast cancer	1.68e-05	0.000227	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOTCH1—breast cancer	1.68e-05	0.000226	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CAV1—breast cancer	1.66e-05	0.000224	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—MAPK3—breast cancer	1.65e-05	0.000222	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KDR—breast cancer	1.65e-05	0.000222	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—NOS3—breast cancer	1.64e-05	0.000221	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—APC—breast cancer	1.64e-05	0.000221	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KIT—breast cancer	1.64e-05	0.000221	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CG—breast cancer	1.64e-05	0.000221	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EGF—breast cancer	1.62e-05	0.000218	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—BRAF—breast cancer	1.62e-05	0.000218	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ESR1—breast cancer	1.6e-05	0.000216	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—FN1—breast cancer	1.58e-05	0.000214	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IGF1—breast cancer	1.58e-05	0.000213	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKT2—breast cancer	1.58e-05	0.000212	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—MAPK3—breast cancer	1.57e-05	0.000212	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—EGFR—breast cancer	1.57e-05	0.000211	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NFKBIA—breast cancer	1.57e-05	0.000211	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—PIK3CA—breast cancer	1.56e-05	0.000211	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MDM2—breast cancer	1.56e-05	0.00021	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—RAF1—breast cancer	1.55e-05	0.000209	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOTCH1—breast cancer	1.55e-05	0.000209	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—RELA—breast cancer	1.55e-05	0.000208	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—BRAF—breast cancer	1.54e-05	0.000208	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—ERBB2—breast cancer	1.54e-05	0.000207	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CG—breast cancer	1.52e-05	0.000204	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KIT—breast cancer	1.52e-05	0.000204	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—APC—breast cancer	1.52e-05	0.000204	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MTOR—breast cancer	1.52e-05	0.000204	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CB—breast cancer	1.52e-05	0.000204	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CD—breast cancer	1.51e-05	0.000204	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IGF1—breast cancer	1.5e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKT2—breast cancer	1.5e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—PIK3CA—breast cancer	1.5e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EGF—breast cancer	1.5e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SERPINE1—breast cancer	1.5e-05	0.000202	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—EGFR—breast cancer	1.49e-05	0.000201	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—KRAS—breast cancer	1.48e-05	0.0002	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CXCL8—breast cancer	1.46e-05	0.000196	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—MAPK3—breast cancer	1.45e-05	0.000196	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—HRAS—breast cancer	1.45e-05	0.000195	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CD—breast cancer	1.44e-05	0.000194	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—NOS3—breast cancer	1.43e-05	0.000193	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—PIK3CA—breast cancer	1.43e-05	0.000192	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—BRAF—breast cancer	1.43e-05	0.000192	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SERPINE1—breast cancer	1.42e-05	0.000192	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN1B—breast cancer	1.42e-05	0.000192	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—KRAS—breast cancer	1.41e-05	0.00019	CbGpPWpGaD
Roflumilast—PDE4C—GPCR downstream signaling—AKT1—breast cancer	1.41e-05	0.00019	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CASP3—breast cancer	1.39e-05	0.000188	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL2—breast cancer	1.39e-05	0.000188	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IGF1—breast cancer	1.39e-05	0.000187	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKT2—breast cancer	1.39e-05	0.000187	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—IL6—breast cancer	1.38e-05	0.000187	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—EGFR—breast cancer	1.38e-05	0.000186	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—PIK3CA—breast cancer	1.36e-05	0.000184	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—NOS3—breast cancer	1.36e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CCND1—breast cancer	1.36e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MDM2—breast cancer	1.36e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—JUN—breast cancer	1.35e-05	0.000183	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—RAF1—breast cancer	1.35e-05	0.000182	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—RELA—breast cancer	1.35e-05	0.000181	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CTNNB1—breast cancer	1.34e-05	0.000181	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—ERBB2—breast cancer	1.34e-05	0.00018	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CD—breast cancer	1.33e-05	0.00018	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—PIK3CA—breast cancer	1.32e-05	0.000178	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MTOR—breast cancer	1.32e-05	0.000178	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CB—breast cancer	1.32e-05	0.000178	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SERPINE1—breast cancer	1.32e-05	0.000178	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MMP9—breast cancer	1.32e-05	0.000178	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—CDKN1A—breast cancer	1.31e-05	0.000177	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PTEN—breast cancer	1.31e-05	0.000177	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—KRAS—breast cancer	1.3e-05	0.000176	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—PIK3CA—breast cancer	1.3e-05	0.000175	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MDM2—breast cancer	1.29e-05	0.000174	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—RAF1—breast cancer	1.29e-05	0.000173	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK8—breast cancer	1.28e-05	0.000173	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—RELA—breast cancer	1.28e-05	0.000173	CbGpPWpGaD
Roflumilast—PDE4C—Signaling by GPCR—AKT1—breast cancer	1.28e-05	0.000172	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—ERBB2—breast cancer	1.27e-05	0.000172	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CXCL8—breast cancer	1.27e-05	0.000171	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—HRAS—breast cancer	1.26e-05	0.00017	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—NOS3—breast cancer	1.26e-05	0.00017	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CB—breast cancer	1.26e-05	0.000169	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MTOR—breast cancer	1.26e-05	0.000169	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN1B—breast cancer	1.24e-05	0.000167	CbGpPWpGaD
Roflumilast—PDE4D—GPCR downstream signaling—AKT1—breast cancer	1.22e-05	0.000165	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—SRC—breast cancer	1.21e-05	0.000164	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CASP3—breast cancer	1.21e-05	0.000164	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL2—breast cancer	1.21e-05	0.000163	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CXCL8—breast cancer	1.21e-05	0.000163	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—IL6—breast cancer	1.21e-05	0.000163	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—PIK3CA—breast cancer	1.2e-05	0.000162	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—HRAS—breast cancer	1.2e-05	0.000162	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MDM2—breast cancer	1.19e-05	0.000161	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—RAF1—breast cancer	1.19e-05	0.00016	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—RELA—breast cancer	1.18e-05	0.00016	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—VEGFA—breast cancer	1.18e-05	0.000159	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CCND1—breast cancer	1.18e-05	0.000159	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—JUN—breast cancer	1.18e-05	0.000159	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN1B—breast cancer	1.18e-05	0.000159	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—ERBB2—breast cancer	1.18e-05	0.000159	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—STAT3—breast cancer	1.17e-05	0.000158	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CTNNB1—breast cancer	1.17e-05	0.000158	CbGpPWpGaD
Roflumilast—PDE4A—GPCR downstream signaling—AKT1—breast cancer	1.17e-05	0.000157	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CB—breast cancer	1.16e-05	0.000157	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MTOR—breast cancer	1.16e-05	0.000157	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CASP3—breast cancer	1.15e-05	0.000156	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL2—breast cancer	1.15e-05	0.000155	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—IL6—breast cancer	1.15e-05	0.000155	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MMP9—breast cancer	1.15e-05	0.000155	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—CDKN1A—breast cancer	1.14e-05	0.000154	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PTEN—breast cancer	1.14e-05	0.000154	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CCND1—breast cancer	1.12e-05	0.000152	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—JUN—breast cancer	1.12e-05	0.000151	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MAPK3—breast cancer	1.12e-05	0.000151	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CXCL8—breast cancer	1.12e-05	0.000151	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK8—breast cancer	1.12e-05	0.00015	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CTNNB1—breast cancer	1.11e-05	0.00015	CbGpPWpGaD
Roflumilast—PDE4D—Signaling by GPCR—AKT1—breast cancer	1.11e-05	0.00015	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—HRAS—breast cancer	1.11e-05	0.00015	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MMP9—breast cancer	1.09e-05	0.000147	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN1B—breast cancer	1.09e-05	0.000147	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—MYC—breast cancer	1.09e-05	0.000147	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—CDKN1A—breast cancer	1.09e-05	0.000147	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TGFB1—breast cancer	1.09e-05	0.000146	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PTEN—breast cancer	1.09e-05	0.000146	CbGpPWpGaD
Roflumilast—PDE4B—GPCR downstream signaling—AKT1—breast cancer	1.08e-05	0.000145	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CASP3—breast cancer	1.07e-05	0.000144	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL2—breast cancer	1.07e-05	0.000144	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—EGFR—breast cancer	1.06e-05	0.000144	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—IL6—breast cancer	1.06e-05	0.000143	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK8—breast cancer	1.06e-05	0.000143	CbGpPWpGaD
Roflumilast—PDE4A—Signaling by GPCR—AKT1—breast cancer	1.06e-05	0.000143	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—SRC—breast cancer	1.06e-05	0.000143	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CCND1—breast cancer	1.04e-05	0.00014	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—JUN—breast cancer	1.04e-05	0.00014	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CTNNB1—breast cancer	1.03e-05	0.000139	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—VEGFA—breast cancer	1.03e-05	0.000139	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—STAT3—breast cancer	1.02e-05	0.000137	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MMP9—breast cancer	1.01e-05	0.000136	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—SRC—breast cancer	1.01e-05	0.000136	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—CDKN1A—breast cancer	1.01e-05	0.000136	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—KRAS—breast cancer	1.01e-05	0.000136	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PTEN—breast cancer	1e-05	0.000135	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK8—breast cancer	9.82e-06	0.000132	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—VEGFA—breast cancer	9.8e-06	0.000132	CbGpPWpGaD
Roflumilast—PDE4B—Signaling by GPCR—AKT1—breast cancer	9.79e-06	0.000132	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MAPK3—breast cancer	9.74e-06	0.000131	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—STAT3—breast cancer	9.7e-06	0.000131	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—MYC—breast cancer	9.47e-06	0.000128	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TGFB1—breast cancer	9.45e-06	0.000127	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—SRC—breast cancer	9.31e-06	0.000126	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MAPK3—breast cancer	9.27e-06	0.000125	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—EGFR—breast cancer	9.27e-06	0.000125	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—PIK3CA—breast cancer	9.24e-06	0.000125	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—VEGFA—breast cancer	9.07e-06	0.000122	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—MYC—breast cancer	9.02e-06	0.000122	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TGFB1—breast cancer	8.99e-06	0.000121	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—STAT3—breast cancer	8.98e-06	0.000121	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—TP53—breast cancer	8.94e-06	0.00012	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—EGFR—breast cancer	8.82e-06	0.000119	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—KRAS—breast cancer	8.75e-06	0.000118	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MAPK3—breast cancer	8.58e-06	0.000116	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—HRAS—breast cancer	8.55e-06	0.000115	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—MYC—breast cancer	8.34e-06	0.000112	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—KRAS—breast cancer	8.33e-06	0.000112	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TGFB1—breast cancer	8.32e-06	0.000112	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—IL6—breast cancer	8.18e-06	0.00011	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—EGFR—breast cancer	8.16e-06	0.00011	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—PIK3CA—breast cancer	8.04e-06	0.000108	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—TP53—breast cancer	7.78e-06	0.000105	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—KRAS—breast cancer	7.71e-06	0.000104	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—PIK3CA—breast cancer	7.65e-06	0.000103	CbGpPWpGaD
Roflumilast—PDE4C—Signaling Pathways—AKT1—breast cancer	7.55e-06	0.000102	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—HRAS—breast cancer	7.44e-06	0.0001	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—TP53—breast cancer	7.4e-06	9.98e-05	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—IL6—breast cancer	7.12e-06	9.6e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—PIK3CA—breast cancer	7.08e-06	9.55e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—HRAS—breast cancer	7.08e-06	9.55e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—TP53—breast cancer	6.85e-06	9.24e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—IL6—breast cancer	6.78e-06	9.14e-05	CbGpPWpGaD
Roflumilast—PDE4D—Signaling Pathways—AKT1—breast cancer	6.57e-06	8.86e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—HRAS—breast cancer	6.55e-06	8.84e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—IL6—breast cancer	6.27e-06	8.46e-05	CbGpPWpGaD
Roflumilast—PDE4A—Signaling Pathways—AKT1—breast cancer	6.25e-06	8.43e-05	CbGpPWpGaD
Roflumilast—PDE4B—Signaling Pathways—AKT1—breast cancer	5.79e-06	7.8e-05	CbGpPWpGaD
